September 6: The Week in Cancer News
Asian American and Pacific Islander women experience rising breast cancer incidence, and a study finds most people diagnosed with cancer will experience cognitive symptoms.
Progress Against Cancer
Asian American and Pacific Islander women experience rising breast cancer incidence, and a study finds most people diagnosed with cancer will experience cognitive symptoms.
Access to high-quality hospitals may be affected by insurance type, and the proliferation of digital tools could increase burdens on patients.
August’s edition of Editors’ Picks includes biomarkers of immunotherapy response, individualized colorectal screening guidelines, and other exciting research.
Early immunotherapy may make more liver cancer patients eligible for surgery, and the FDA approves a new use for a lung cancer treatment.
The FDA approved lazertinib plus amivantamab-vmjw for the treatment of certain EGFR-mutated lung cancers. The U.S. Food and Drug Administration (FDA) has approved lazertinib (Lazcluze), in combination with amivantamab-vmjw (Rybrevant), for the first-line treatment...
Durvalumab can now be used with chemotherapy for certain patients with resectable non-small cell lung cancer. The U.S. Food and Drug Administration (FDA) has granted approval to the neoadjuvant combination of durvalumab (Imfinzi) and...
Immunotherapy may make surgery an option for patients who would be considered ineligible under traditional rules. Surgery is usually the best treatment for early-stage hepatocellular carcinoma, the most common type of liver cancer, but...
The FDA approved axatilimab-csfr, an inhibitor of monocytes and macrophages, for certain patients with chronic graft-versus-host disease. The U.S. Food and Drug Administration (FDA) has approved axatilimab-csfr (Niktimvo) for the treatment of adult and...
More endometrial cancer patients can now receive an immunotherapy, and taking aspirin regularly may help some people reduce their risk for colorectal cancer.
The FDA has approved vorasidenib to treat certain brain tumors harboring an IDH1 or IDH2 mutation. The U.S. Food and Drug Administration (FDA) has approved vorasidenib (Voranigo) for the treatment of adult and pediatric...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More